Research Topics
| Joseph A M J L JanssenSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Igf-I and longevityJ A M J L Janssen
Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
Horm Res 62:104-9. 2004..For each individual there is probably a specific optimal 'setpoint' for the insulin/growth hormone/IGF-I axis which co-determines survival...
Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients With Graves' OphthalmopathyAimee J Varewijck
MD, PhD, Department of Internal Medicine, Erasmus MC, Room D 443, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
J Clin Endocrinol Metab 98:769-76. 2013..In a subgroup of these patients, depletion of IgGs significantly decreased IGF-IR stimulating activity, suggesting that, in a subset of patients with GO, IgGs may have IGF-IR stimulating activities...- IGF-I Bioactivity Might Reflect Different Aspects of Quality of Life Than Total IGF-I in GH-Deficient Patients During GH TreatmentAimee J Varewijck
MD, PhD, Department of Internal Medicine, Erasmus Medical Center, Room D 443, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
J Clin Endocrinol Metab 98:761-8. 2013..This suggests that IGF-I bioactivity reflects different aspects of QOL than total IGF-I in GHD patients during GH treatment... 
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarlyA J Varewijck
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
Diabetologia 55:1186-94. 2012....- Advantages and disadvantages of GH/IGF-I combination treatmentJ A M J L Janssen
Department of Internal Medicine, Erasmus MC, Room D425, Rotterdam, The Netherlands
Rev Endocr Metab Disord 10:157-62. 2009..However, determination of whether co-administration of GH and IGF-I indeed is superior to either agent alone awaits further study... - Insulin-like growth factor I: pros and cons of a bioassayJ A M J L Janssen
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
Horm Res Paediatr 76:106-10. 2011..However, IGF-I KIRA undoubtedly will provide new insights into the factors that regulate IGF-I bioactivity in the circulation in both healthy and diseased states... - There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patientsJ A M J L Janssen
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
J Endocrinol Invest 27:659-64. 2004..This suggests that GH-independent effects of ghrelin play no important role in the acute regulation of cardiac function in man... - [Still no indications that the treatment of growth hormone deficient adults with growth hormones is unsafe]J A M J L Janssen
Erasmus Medisch Centrum, afd Inwendige Geneeskunde, sectie Endocrinologie, Dr Molewaterplein 40, 3015 GD Rotterdam
Ned Tijdschr Geneeskd 148:1486-9. 2004..Whether growth-hormone therapy in adult patients with GHD will prove safe in the long term remains to be established... - Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with aJ A M J L Janssen
Department of Internal Medicine, Room D 436, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
J Clin Endocrinol Metab 89:4391-6. 2004..In addition, our results indicate that the endocrine IGF-I system is not directly involved in the growth of the early stages of prostate cancer... - Is there a role of ghrelin in preventing catabolism?J A M J L Janssen
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
J Endocrinol Invest 27:400-3. 2004..In conclusion, the anabolic effects of ghrelin in man have still to be demonstrated... - Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivityJ A M J L Janssen
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
J Endocrinol Invest 26:588-94. 2003..Therefore, when evaluating the IGF-I bioactivity in health and disease, we recommend measuring also circulating free IGF-I... - Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegalyJ Feenstra
Department of Internal Medicine, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, Netherlands
Lancet 365:1644-6. 2005..This combined treatment is effective, might increase compliance, and could greatly reduce the costs of medical treatment for acromegaly in some patients... - Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndromeMichael P Brugts
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
Diabetes 59:505-8. 2010..The purpose of our study was to investigate whether IGF-I bioactivity was related to insulin sensitivity and the metabolic syndrome... - Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signallingAimee J Varewijck
Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
Mol Cell Endocrinol 365:17-24. 2013..The aim of this study was to determine total serum insulin-like activity mediated via the insulin receptor isoform A (IR-A) and isoform B (IR-B) by using kinase receptor activation (KIRA) assays specific for the IR-A and IR-B... - Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassaysMichael P Brugts
Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 50, Rotterdam, The Netherlands
J Clin Endocrinol Metab 93:2539-45. 2008..Recently an IGF-I-specific kinase receptor activation assay (KIRA) has been developed as an alternative method. However, no normative values have been established for the IGF-I KIRA... - Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivityC Gauna
Department of Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
J Clin Endocrinol Metab 89:5035-42. 2004.... - Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortalityM P Brugts
Department of Internal Medicine, Erasmus Medical Center, Dr Molewaterplein 50, Rotterdam, The Netherlands
J Clin Endocrinol Metab 93:2515-22. 2008..The IGF-I kinase receptor activation assay is a novel method for measuring IGF-I bioactivity in human serum. We speculated that determination of circulating IGF-I bioactivity is more informative than levels of immunoreactive IGF-I... - Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patientsS J C M M Neggers
Department of Medicine, Erasmus University, Erasmus MC, Rotterdam, The Netherlands
Eur J Endocrinol 160:529-33. 2009..We previously reported on the efficacy, safety, and quality of life (QoL) of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA... - Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levelsR A Feelders
Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
J Clin Endocrinol Metab 90:6480-9. 2005..It is not exactly known when patients with acromegaly should be evaluated for cure after transsphenoidal adenomectomy (TA)... - Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomantS J C M M Neggers
Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
J Clin Endocrinol Metab 93:3853-9. 2008.... - Insulin and its analogues and their affinities for the IGF1 receptorAimee J Varewijck
Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, CE Rotterdam, The Netherlands
Endocr Relat Cancer 19:F63-75. 2012..More detailed information is required to elucidate the exact mechanisms as to how insulin analogues may activate the IR and IGF1R and how this activation may be linked to mitogenesis... - An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose toleranceI Rietveld
Department of Internal Medicine, Rotterdam, The Netherlands
Eur J Endocrinol 154:715-21. 2006..Microalbuminuria (MA) is related to cardiovascular disease both in diabetic patients and non-diabetic subjects... - The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?J A M J L Janssen
Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
Eur J Endocrinol 146:467-77. 2002..Clinical trials are necessary to prove that long-term IGF-I treatment, preferably in the form of a better-tolerated IGF-I/IGF-binding protein-3 complex, improves the overall cardiovascular risk in type 2 diabetes... - A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body heightI Rietveld
Department of Internal Medicine, Erasmus MC Rotterdam, The Netherlands
Clin Endocrinol (Oxf) 61:195-203. 2004..A polymorphism near the promoter region of the IGF-I gene has been associated with serum IGF-I levels, age-related decline of serum IGF-I levels, body height, birth weight and intima media thickness in hypertensive subjects... - Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patientsMichael P Brugts
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
Nephrol Dial Transplant 25:940-6. 2010..Aim of the study. The aim of the study was to investigate in CAPD patients whether circulating insulin-like growth factor-I (IGF-I) bioactivity may offer a more sensitive index to acute nutritional interventions than total IGF-I... - IGF-I bioactivity better reflects growth hormone deficiency than total IGF-IA J Varewijck
Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
J Clin Endocrinol Metab 96:2248-54. 2011..Recently a kinase receptor activation assay was developed to determine IGF-I bioactivity in human serum. The principle of this assay is based on quantification of IGF-I receptor activation after stimulation with serum in vitro... - IGF-1 CA repeat variant and breast cancer risk in postmenopausal womenA M González-Zuloeta Ladd
Epidemiology and Biostatistics Department, Erasmus MC, Rotterdam, The Netherlands
Eur J Cancer 43:1718-22. 2007..26 (95% CI=0.95-1.82) for IGF-I CA(19) non-carriers versus CA(19) homozygous carriers. According to these results, the IGF-I CA(19) promoter polymorphism is not likely to predict the risk of breast cancer... - Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivorsF de Groof
Department of Pediatrics, Division of Pediatric Intensive Care, Sophia Children's Hospital, Erasmus University Medical Center, 3000 CB Rotterdam, The Netherlands
J Clin Endocrinol Metab 87:3118-24. 2002..These values were different from those for the survivors. Based on these findings and literature data a hypothetical model was constructed summarizing our current knowledge and understanding of the various mechanisms... - [Hepatocellular carcinoma complicated by non-islet cell tumor hypoglycemia]P van Wijngaarden
Academisch Ziekenhuis Rotterdam-Dijkzigt, Postbus 2040, 3000 CA Rotterdam
Ned Tijdschr Geneeskd 146:859-62. 2002..Therefore, growth hormone was added to the treatment which resulted in a complete disappearance of the hypoglycaemias. The patient died within 6 months of the diagnosis having been established... - A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophyG S Bleumink
Heart 91:239-40. 2005 - Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertensionA F C Schut
Department of Epidemiology, Erasmus Medical Center Rotterdam, Netherlands
Stroke 34:1623-7. 2003..We examined the role of this polymorphism in relation to blood pressure and 2 early markers of atherosclerosis: carotid intima-media thickness (IMT) and aortic pulse wave velocity (PWV)...